Hemiasterlin

Hemiasterlin

SCHEMBL4173

CNC(C(=O)N[C@H](C(=O)N(C)[C@H](/C=C(\C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)c1cn(C)c2ccccc12

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 2/20 0.61
GLA P06280 1/20 0.33
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NR4A2 P43354 1/20 0.31
POLB P06746 1/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
STAT6 P42226 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hemiasterlin SCHEMBL22692376 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL14567797 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL13850381 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL57334 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL57313 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL29421592 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL14115433 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
Hemiasterlin SCHEMBL13203800 1.00 TUBB1 (0.61) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
SCHEMBL26607783 0.94 TUBB1 (0.53) TUBB1GLAALDH1A1SMN1; SMN2NR4A2
SCHEMBL58604 0.93 TUBB1 (0.52) TUBB1GLAALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4643 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083866-A1 COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2026-03-26 US claimed
EP-4714971-A1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-03-25 EP claimed
EP-4704904-A1 TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD Tambo, Inc. (US) 2026-03-11 EP claimed
EP-4695300-A2 ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF A & G Pharmaceutical, Inc. (US) 2026-02-18 EP claimed
EP-4684807-A1 LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE Duality Biologics (Shanghai) Co., Ltd. (CN) 2026-01-28 EP claimed
US-20260007763-A1 PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE SHENZHEN ENDURING BIOTECH, LTD. (CN) 2026-01-08 US claimed
US-20260001950-A1 METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN MEDICOVESTOR INC (US) 2026-01-01 US claimed
US-20250387499-A1 LIGAND-PAYLOAD CONJUGATES PYXIS ONCOLOGY, INC. (US) 2025-12-25 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-0839154-B1 BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE UNIV BRITISH COLUMBIA (CA) 2003-12-17 EP claimed
WO-2003082268-A2 HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER EISAI CO. LTD (JP) 2003-10-09 WO claimed
WO-2003072754-A2 CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2003-09-04 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-1263762-A4 ANTI-INFECTIVE ECTATM NEWBIOTICS INC (US) 2003-04-02 EP claimed
EP-1263762-A1 ANTI-INFECTIVE ECTATM Newbiotics Inc. (US) 2002-12-11 EP claimed
WO-2001064687-A1 ANTI-INFECTIVE ECTA?TM¿ NEWBIOTICS, INC. (US) 2001-09-07 WO claimed
EP-0839154-A1 BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1998-05-06 EP claimed
US-5661175-A ANTITUMOR AGENTS; CYTOTOXIC PEPTIDES PHARMA MAR, S.A. (ES) 1997-08-26 US claimed
WO-1996033211-A1 BIOLOGICALLY ACTIVE PEPTIDES AND COMPOSITIONS, THEIR USE UNIVERSITY OF BRITISH COLUMBIA (CA) 1996-10-24 WO claimed